For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies.
When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform.
In return, we’ll help you build a career that you can feel passionate about.
At Charles River we work at the forefront of Drug Discovery, combining experimental laboratory-based ADME sciences with informatics, in vitro pharmacology and medicinal chemistry capability, in a pioneering commercial environment.
An opportunity has arisen for a technician to join the Drug Metabolism and Pharmacokinetics (DMPK) team to expand the resource within the department.
The ideal candidate will have some understanding of laboratory work, be adaptable, enthusiastic and have excellent communication, organization and time management skills.
This position is ideally suited for an undergraduate / school leaver looking to gain practical experience before entering higher education.
There may be the potential for access to a further education course within the role, if appropriate.
In this lab based role your main duties will be, following comprehensive training, to analyse biological samples using liquid chromatography mass spectrometry in accordance with defined experimental procedures and process and summarise results for quality control by others.
You will also perform general laboratory housekeeping and routine instrument validation and maintenance duties to ensure compliance with quality management systems and to maintain a safe working environment for you and your colleagues.
Closing deadline 24 May 2019.
Discovery from Charles River is industry-proven in the successful development of novel therapies, with over 320 patents and 74 preclinical drug candidates delivered to our sponsors in the past 17 years.
Backed by more than 650 scientists, our comprehensive, integrated portfolio employs the latest technology and platforms to provide chemistry, biology, and pharmacology services that support clients from the earliest stages of hit identification all the way through to IND.
Our client-focused, collaborative approach creates true partnerships that anticipate challenges, overcome obstacles, and move us forward together on the journey of getting new drugs to market.
About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-
GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities.
Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 14,000 employees within 80 facilities in 20 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges.
Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world.
And in 2018, revenue increased by 22% to $2.27 billion from $1.86 billion in 2017.
At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-
being of many across the globe. We have proudly supported the development of 85% of the drugs approved by the FDA in 2018.